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A novel radioiodinated ligand of the butyrophenone type has been synthesized for the quantification and 
characterization f dopamine D 2 receptors. This haloperidoi-derived ligand, haloperidol-succinylglycyl- 
[125I]iodotyrosine ([lZSI]HSGTI), binds rapidly (equilibrium is reached within 30 min, at 10 pM and 37 °C) 
and with high affinity (Kd = 0.3 nM) to bovine striatal membranes. Its pharmacology, determined by com- 
petitive displacement with dopaminergic and non-dopaminergic drugs, is characteristic of binding to 
dopamine D2 receptors. 
Dopamine D2 receptor; Radioiodinated ligand; (Striatum) 
1. INTRODUCTION 
Until recently, no iodinated compound had been 
proposed for the investigation of dopaminergic 
receptors. Several tritiated ligands have been used 
to label them, allowing knowledge to be gained 
concerning their pharmacology. The results ob- 
tained from binding experiments using a great 
variety of antagonist and agonist molecules, cor- 
related with functional data (adenylate cyclase ac- 
tivity), have led to the definition of two classes of 
dopaminergic receptors, termed D1 and D2 [1,2]. 
Both classes display two states of agonist affinity 
[3-5]. However, during the last 3 years, three 
iodinated rugs have been developed: 125I-sulpride 
[6], a benzamide derivative, and two 
butyrophenone d rivatives, ~25I-spiperone [7] and 
125I-NAPS [8]. 125I-NAPS is a convenient covalent 
photoaffinity probe. Here, we present the develop- 
ment of another iodinated compound of the 
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butyrophenone class: haloperidol-succinylglycyl- 
[125I]iodotyrosine ([125I]HSGTI), and its character- 
ization using bovine striata. This iodinated 
derivative was devised not only as a ligand of 
dopaminergic receptors, but also as a radioactive 
tracer for the radioimmunoassay (RIA) of small 
amounts of haloperidol in small brain tissue 
samples and in serum samples (unpublished). 
2. MATERIALS AND METHODS 
The radioactive materials used in these studies 
were from commercial sources: NalZSI (carrier- 
free) and [3H]spiperone (1 TBq/mmol) were ob- 
tained from New England Nuclear (Dreieich, 
FRG). Most of the drugs were generous gifts from 
laboratories: Janssen Pharmaceutica (Beerse, 
Belgium), Lundbeck (Copenhagen, Danmark), 
Organon (Oss, The Netherlands) and SKF 
(Welwyn, England). Dopamine was from Sigma 
(St. Louis, USA), and butaclamol from Ayerst 
Laboratories (Montreal, Canada). All given pH 
values were determined at 25°C. 
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2.1. [~25I]HSGTI synthesis 
The formation of haloperidol-hemisuccinate h s 
been described elsewhere [91. The coupling to 
glycyltyrosine was achieved as follows: 
haloperidol-hemisuccinate (10/zmol) in 1 ml 
acetonitrile containing triethylamine (20/~mol) was 
activated with ethylchloroformate (20/zmol) for 
5 min at 4°C. 1 ml of a solution of glycyl-L- 
tyrosine (50/~mol) in acetonitrile/0.2 M tri- 
ethylamine (50:50) was added to the activated 
solution with stirring. After 15 min, the mixture 
was purified by HPLC on a C18 column, using 
acetonitrile/10 mM ammonium acetate, pH 6.2 
(50:50), as the mobile phase. The relevant 
haloperidol-succinylglycyltyrosine (HSGT) frac- 
tions were pooled, the acetonitrile vaporated and 
the resulting solution freeze-dried. HSGTI was ob- 
tained by iodination of HSGT by a standard 
chloramine T procedure and purified by HPLC on 
a C 18 column, using acetonitrile/10 mM 
potassium phosphate, pH 6.2 (40:60), as the sol- 
vent system. HSGT and HSGTI were identified by 
UV spectrophotometry by comparing their spectra 
with those of solutions containing a mixture of the 
same amounts of haloperidol and glycyltyrosine, 
or of haloperidol and glycyliodotyrosine. The 
radioactive compound was synthesized from 
HSGT by the same procedure. In this case, 10/zCi 
Na~25I and 10 nmol chloramine T were added to 
1 nmol HSGT in 50 mM potassium phosphate 
buffer, pH 7.2. The reaction was stopped after 
1 min by adding 50 nmol metabisulfite. The 
monoiodinated compound [~25I]HSGTI was iden- 
tified by HPLC by comparing its retention time 
with that of HSGTI. The purified fraction was 
diluted to 600000 cpm/ml in 50 mM Tris-HC1, pH 
7.4, and stored at -20°C.  Due to the complete 
separation of the iodinated erivative from Na~25I 
and HSGT, the specific activity of [~25I]HSGTI 
was assessed as 2175 Ci/mmol. 
2.2. Bovine striatal membranes 
Fresh bovine brains were obtained from a local 
slaughterhouse. Striata were removed as rapidly as 
possible and homogenized in 10 vols (w/v) of ice- 
cold 10 mM Tris-HC1, pH 7.4, containing 320 mM 
sucrose and 10 mM MgCI2. The homogenate was 
centrifuged at 1000 × g for 10 min and the 
resulting supernatant was spun at 27000 × g for 
30 min. The resulting pellet was resuspended in
ice-cold 50 mM Tris-HC1, pH 7.4, and stored at 
- 20oc. 
2.3. Binding studies 
Incubations were carried out, in a total volume 
of 250/zl, in 50 mM Tris-HCl, pH 7.4, 30 mM 
MgC12 (unless stated otherwise). The incubation 
media contained [125I]HSGTI at the appropriate 
concentration, the membrane preparation (ap- 
prox. 25/~g protein) with or without 1/zM (+)-  
butaclamol (to define non-specific binding), or 
with various concentrations of different com- 
petitors. After incubation at 37°C for 40 min (or 
for the indicated times), the bound ligand was 
separated from the free ligand by centrifugation at
8700 × g for 1 min at 4°C. Aliquots of the super- 
natant were taken to estimate the free ligand. The 
pellet was superficially washed with 1 ml ice-cold 
buffer and recentrifuged. The bottom of the tubes 
containing the pellets were cut before counting. 
No hydrolysis of [~25I]HSGTI was detected by 
HPLC during the incubation (30 min) with brain 
membranes. Experimental data were fitted using a 
Hewlett-Packard HP 9845 calculator and com- 
puting programs developed in the laboratory [10]. 
The curves were fitted using all individual data, ex- 
cept for the competition curves (12-16 concentra- 
tions of displacing drug) represented in fig.3, 
which were drawn using the mean of the triplicate 
values for each concentration. 
3. RESULTS AND DISCUSSION 
3.1. Kinetics and equilibrium binding data 
The binding of [lzsI]HSGTI was linear over a 
large range of protein concentrations: 
20-500/tg/ml.  [lzsI]HSGTI bound rapidly to 
bovine striatal membranes, reaching equilibrium 
within 30 min at 10 pM and within 6 min at 4 nM 
(fig.lA). Binding was then stable for at least 
60 min. Specific binding represented 60% of the 
total binding at 10 pM, and 40% at 1 riM. The 
association rate constant kl was determined to 
equal 0.12 × 109 mol - l .min  -~. The dissociation 
rate was also examined (fig.lB). The dissociation 
rate constant k-1 was determined to be equal to 
0.06 min -a, with a tl/z = 12 min. The equilibrium 
dissociation constant deduced from these kinetic 
data was Kd -- k-1/kl = 0.50 nM. This constant 
was also determined by equilibrium binding as seen 
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Fig.l .  Kinetics of [125I]HSGTI binding to bovine striatal 
membranes. Membranes were incubated as described in 
section 2, with [125I]HSGTI at 4 riM, for the association 
kinetics (A), and 40 pM, for the dissociation kinetics 
(B). At the indicated times, samples were centrifuged for 
1 min at 4°C to measure bound ligand. In B, the 
dissociation was initiated, after an equilibration of 
30 min with [125I]HSGTI, by the addition of 1 #M (+)-  
butaclamol to the incubation mixtures. 
in fig.2. The equi l ibr ium parameters derived f rom 
the exper imental  values were Kd ---- 0.30 _+ 0.04 nM 
and Bmax = 192 + 15 fmo l /mg protein.  The 
dissociat ion constants obtained by both pro- 
cedures were of  the same order of  magnitude.  
The opt imum specific binding was observed only 
in the presence of  20-30  mM divalent cat ion 
(Ca 2÷, Mg 2÷, or Mn2+). The monovalent  cations, 
K ÷ and Li ÷, were less effective in potent iat ing 
specific binding, while Na ÷ even inhibited it, con- 
trast ing with its act ion on sulpir ide binding (table 
1) [12]. 
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Fig.2. Saturation binding isotherm for [125I]HSGTI. 
Bovine striatal membranes (25 #g) were incubated as 
described in section 2 with increasing concentrations of
[n25I]HSGTI. Incubations were carried out at 37°C for 
15 min. (Inset) Scatchard plot of the data. 
Table 1 
Dissociation constants of dopaminergic and non- 
dopaminergic drugs 
Drugs Inhibition constants 
gi (nM) 
Haloperidol 2 +_ 0.5 
Spiperone 0.6 _+ 0.1 
(+)-Butaclamol 0.9 _+ 0.1 
( - )-Butaclamol > 10000 
Domperidone 2 _+ 0.5 
Suipiride 1590 +_ 318 
Sulpiride + 100 mM NaC1 190 +_ 75 
Flupentixol 23 +_ 8 
SCH 23390 4250 +_ 1700 
SKF 38393 1074 +_ 260 
Dopamine 2760 _+ 520 
Mianserine > 40000 
Alprenolol > 30000 
Prazosine 1700 +_ 600 
Yohimbine 2500 _+ 1000 
[12SI]HSGTI (40 pM) was used to determine IC50 values. 
Because of the low concentration of the tracer, Ki values 
were considered to be close to the ICso values 
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Fig.3. Competition curves of a series of dopaminergic 
antagonists for the binding of [125I]HSGTI (40 pM) to 
bovine striatal membranes: (e) domperidone, (+) 
haloperidol, (A) spiperone, (~t) sulpiride. Binding is 
expressed as the percentage of the specific binding of 
controls which, depending on the experiment, 
corresponded to 3-6 pM bound [125I]HSGTI. 
3.2. Specificity of [125I]HSGTI binding 
Competition experiments with dopaminergic D2 
antagonists are illustrated in fig.3 and table 1. The 
rank order of potency observed for the displace- 
ment of [125I]HSGTI by these compounds was 
similar to that described for [3H]spiperone [2] and 
[3H]haloperidol [13,14] displacements: spipe- 
rone > (+)-butaclamol > domperidone > 
haloperidol > sulpiride > (-)-butaclamol.  The 
ligands specific for the D1 receptors, such as SCH 
23390 and SKF 38393 [15], had low affinities for 
[XESI]HSGTI-binding sites. Likewise, ligands 
specific for serotoninergic (mianserin), /]- 
adrenergic (alprenolol), or CrE-adrenergic (yohim- 
bine) receptors were inefficient in displacing 
[125I]HSGTI from bovine striatal membranes. 
Haloperidol has been described as competing with 
high affinity for Cel-adrenergic sites [16]. However, 
its new iodinated erivative did not seem to bind to 
these sites (at least at the concentrations explored) 
since prazosin displaced [125I]HSGTI binding only 
in the micromolar concentration range despite 
known binding to oe~-adrenergic sites in the 
nanomolar range [17]. 
This novel iodinated ligand therefore offers 
good DE dopaminergic specificity. The coupling of 
haloperidol to the dipeptide glycyltyrosine does 
not alter the affinity of the neuroleptic for 
dopaminergic sites. A similar observation was 
made by Jacobson et al. [18] for a series of 
derivative antagonists of adenosine receptors, ob- 
tained by covalent binding of amino acids to a xan- 
thine backbone. The high specific activity of 
[125I]HSGTI should allow the measurement of 
D2-binding sites in small membrane samples 
prepared either from cultured cells, or from pun- 
ches of brain tissue. Data obtained from 
measurements in samples taken from the central 
nervous system, combined with the RIA deter- 
mination of haloperidol levels in equivalent 
material using the same ligand, should allow the 
direct comparison of receptor densities and 
haloperidol distributions in different brain regions 
following, for instance, an experimental treatment 
of rats with this neuroleptic. 
ACKNOWLEDGEMENTS 
This work was supported by grants from the 
Scientific Council of the University Bordeaux II 
and from the MIR no.2891. Part of this work was 
presented in the thesis of F.G. at the University of 
Bordeaux II in 1986. 
REFERENCES 
[1] Kebabian, J.W. and Calne, D.B. (1979) Nature 
277, 93. 
[2] Seeman, P. (1980) Pharmacol. Rev. 32, 229-313. 
[3] Hamblin, M.W., Leff, S.E. and Creese, I. (1984) 
Biochem. Pharmacol. 33, 877-887. 
[4] Leff, S.E., Hamblin, M.W. and Creese, I. (1985) 
Mol. Pharmacol. 27, 171-183. 
[5] Urwyler, S. and Markstein, R. (1986) J. 
Neurochem. 46, 1058-1067. 
[6] Martres, M.P., Bouthenet, M.L., Sales, N., 
Sokoloff, P. and Schwartz, J.C. (1985) Science 
228, 752-754. 
[7] Gundlach, A.L., Largent, B.L. and Snyder, S.H. 
(1984) Life Sci. 35, 1981-1988. 
[8] Amlaiky, N. and Caron, M.G. (1985) J. Biol. 
Chem. 260, 1983-1985. 
[9] Garrigues, A.M., Stinus, L., Taghzouti, K., 
Simon, H., Le Moal, M. and Delaage, M. (1985) 
Eur. J. Pharmacol. 118, 313-319. 
270 
Volume 224, number 2 FEBS LETTERS November 1987 
[10] Voisin, P.J., Girault, J.M., Labouesse, J. and 
Viratelle, O.M. (1987) Brain Res. 404, 65-79. 
[11] Stefanini, E., Marchisio, A.M., Devoto, P., 
Vernaleone, F., Collu, R. and Spano, P.F. (1980) 
Brain Res. 198, 229-233. 
[12] Creese, I., Schwarcz, R., Coyle, J.T. and Snyder, 
S.H. (1977) Soc. Neurosci. abstr. 3,454. 
[13] Burt, D.R., Creese, I. and Snyder, S.H. (1976) 
Mol. Pharmacol. 12, 800-812. 
[14] Leysen, J.E. and Commeren, W. (1984) J. 
Receptor Res. 4 (7), 817-845. 
[15] O'Boyle, K.M. and Waddington, J.L. (1984) Eur. 
J. Pharmacol. 98, 433-436. 
[16] U'Prichard, D.C., Greenberg, D.A. and Snyder, 
S.H. (1977) Mol. Pharmacol. 13,454-473. 
[17] Sebben-Perez, M., Ebersol, T.C., Blanc, G. and 
Bockaert, J. (1984) Neurochem. Int. 6, 103-108. 
[18] Jacobson, K.A., Kirk, K.L., Padgett, W.L. and 
Daly, J.W. (1986) Mol. Pharmacol. 29, 126-133. 
271 
